Eli Lilly and Company 10-Qquarter ended 2026-09-30

Executive Summary

Eli Lilly sells prescription medicines for patients with diabetes, obesity, cancer and other diseases, earning revenue from product sales and collaborations. It is expanding its obesity and diabetes franchise through Mounjaro, Zepbound, newly launched Foundayo and additional manufacturing capacity, while buying experimental medicines to broaden its pipeline. Q3 revenue rose 39%, but net income grew 16% as acquired research charges absorbed much of the additional profit. The opportunity is wider treatment access and new medicines; the investor question is whether volume growth can continue overcoming lower prices while funding Lilly’s expansion.

What's Happening in the Business

Demand for Mounjaro and Zepbound continued to dominate growth. Across Lilly, volume contributed 53 percentage points to Q3 revenue growth, while lower realized prices subtracted 15 points. Outside the U.S., Mounjaro’s inclusion on China’s National Reimbursement Drug List expanded access but reduced realized prices, illustrating the trade-off between reaching more patients and earning less per prescription.

Lilly is extending this franchise beyond its existing injectable treatments. Foundayo, its oral obesity medicine, launched in the U.S. in Q2, with international launches and submissions expanding. Regulatory approvals also included Onswik for type 2 diabetes and tirzepatide for cardiovascular-risk reduction in type 2 diabetes. Retatrutide’s Phase 3 trials met their primary endpoints in obesity and type 2 diabetes, supporting another potential source of growth rather than an approved revenue stream.

Manufacturing expansion is consuming more capital, with additional capacity expected over several years. At the same time, Lilly spent $18.2B on business development during 9M, including acquisitions extending its pipeline into cell therapy, sleep-wake disorders and inflammatory disease. These investments broaden its scientific opportunities but commit substantial resources before commercial success is established.

Key Financial Highlights

• Growth concentration: Mounjaro revenue reached $10.7B, +65%, and Zepbound $5.35B, +49%; together they supplied 88% of the quarterly revenue increase. These products, rather than the smaller therapeutic areas, determined the overall result.
• Gross margin: Q3 reached 83.9%, up 100 bp, as improved production costs and product mix outweighed lower prices. R&D expense rose 23% to $4.25B as Lilly invested in its pipeline.
• Cash deployment: 9M capital expenditures were $8.44B, +59%, leaving FCF of $19.0B. Acquisition payments of $10.7B and acquired-research purchase payments of $7.55B were additional investing outflows; OCF therefore overstates cash available after pipeline investment.
• Funding: Debt, carrying amount including current maturities, rose 16% from year-end to $49.5B, while cash fell to $4.89B. Acquisition funding helped drive borrowing, and quarterly interest expense rose to $378M from $180M.

Risk Assessment

• Incretin concentration and access: Mounjaro, Zepbound and Foundayo represented 66% of 9M revenue, making payer restrictions, competition, compounded products and pricing concessions unusually consequential.
• Government pricing: Government-set prices apply to Jardiance beginning in 2026 and Trulicity and Verzenio in 2028; broader intervention could weaken economics even as treatment volumes grow.
• Pipeline and financing exposure: Heavy acquisition spending, higher debt and milestone-dependent obligations increase the cost of clinical failures; preliminary acquisition valuations also leave room for later revisions.
• Manufacturing execution: Capacity additions must meet regulatory requirements and arrive in time to serve demand, while disruptions or delays could constrain sales.
• Litigation: Incretin product-liability claims, patent challenges and insulin-pricing and 340B disputes could affect exclusivity or produce material charges, with Lilly predominantly self-insured.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

What to Watch

• Foundayo adoption: Following its U.S. launch, subsequent filings should show whether oral obesity treatment broadens Lilly’s customer base and international sales, or struggles to gain access and uptake.
• Access versus pricing: The Medicare GLP-1 Bridge began on 7/1/2026 and runs through 12/31/2027. Success would mean added volume sustains growth despite discounts; failure would show price concessions without sufficient uptake.
• Manufacturing expansion: Capital spending is elevated and capacity arrives over several years. Watch whether product growth and production efficiency improve as facilities become available, rather than spending rising without usable supply.
• Acquired pipeline progress: The newly purchased programs must advance through clinical and regulatory milestones. Progress would diversify future revenue opportunities; setbacks, discontinued programs or write-downs would expose the cost of buying that optionality.